This statement is made pursuant to Section 54, Part 6 of the Modern Slavery Act 2015 and sets out the steps the Company has taken to ensure that slavery and human trafficking is not taking place in our supply chains or in any part of our business.

As we have expanded with the merger of Idis and Link, Clinigen has become a worldwide supplier and distributor of pharmaceutical products and services. As part of our initiative to identify and mitigate risk we have, or are in the process of putting in place, systems to:

  • Identify and assess potential risk areas in our supply chains
  • Mitigate the risk of slavery and human trafficking occurring in our supply chains
  • Monitor potential risk areas in our supply chains
  • Protect whistle blowers

The Group will continue to review the position by a process of contract reviews, third party audits and an ongoing monitoring of our partners within the supply chain.